文献速递哮喘

阿奇霉素减少未控制哮喘急性发作的成本效益

The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma.
PubMed 文献 · Eur Respir J · 2021-02-17

基于AMAZES试验420例成人持续性未控制哮喘患者,评估加用阿奇霉素(AZM)相对于安慰剂的医疗与社会成本效益。结果显示加用AZM降低医疗成本(住院、非计划就诊、抗生素及口服激素费用均显著降低),净货币效益在避免每次急性发作的支付意愿为2651澳元时估计为2072.30澳元,且敏感性分析中净货币效益保持正向显著,提示该治疗具有成本效益。

要点

  • 加用阿奇霉素可显著降低未控制哮喘患者的住院、非计划就诊及药物成本。
  • 净货币效益在多种敏感性分析中均为正且显著,支持其成本效益。
  • 抗菌药物耐药相关成本未影响成本效益估计。

核心结论

  • 在控制不佳的哮喘患者中,加用阿奇霉素治疗具有成本效益。
  • 抗菌药物耐药相关成本未影响估计的成本效益。

研究设计与样本

  • 基于AMAZES试验的成本效益分析,该试验随机分配420名参与者至阿奇霉素组或安慰剂组。
  • 收集治疗期间医疗资源使用和哮喘急性发作数据,估算医疗成本和社会成本。

主要发现

  • 加用阿奇霉素降低住院夜数相关成本:平均差值433.70澳元(95%CI 48.59-818.81)或260.22欧元(95%CI 29.15-491.29),p<0.05。
  • 降低非计划就诊成本:平均差值20.25澳元(95%CI 5.23-35.27)或12.15欧元(95%CI 3.14-21.16),p<0.05。
  • 降低抗生素成本:平均差值14.88澳元(95%CI 7.55-22.21)或8.93欧元(95%CI 4.53-13.33),p<0.05。
  • 降低口服糖皮质激素成本:平均差值4.73澳元(95%CI 0.82-8.64)或2.84欧元(95%CI 0.49-5.18),p<0.05。
  • 总体医疗成本和社会成本分别降低77.30澳元(46.38欧元)和256.22澳元(153.73欧元),但无统计学显著性。

关键数值与推荐

  • 净货币效益估计为2072.30澳元(95%CI 1348.55-2805.23)或1243.38欧元(95%CI 809.13-1683.14),假设避免每次急性发作的支付意愿为2651澳元(1590.60欧元)。
  • 无论采用何种敏感性分析,总、中度和重度急性发作的净货币效益均保持正向且显著。

临床怎么用

  • 对于持续性未控制哮喘成人患者,可考虑加用阿奇霉素以减少急性发作并降低医疗成本。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Add-on azithromycin (AZM) results in a significant reduction in exacerbations among adults with persistent uncontrolled asthma. The aim of this study was to assess the cost-effectiveness of add-on AZM in terms of healthcare and societal costs.The AMAZES trial randomly assigned 420 participants to AZM or placebo. Healthcare use and asthma exacerbations were measured during the treatment period. Healthcare use included all prescribed medicine and healthcare contacts. Costs of antimicrobial resistance (AMR) were estimated based on overall consumption and published estimates of costs. The value of an avoided exacerbation was based on published references. Differences in cost between the two groups were related to differences in exacerbations in a series of net monetary benefit estimates. Societal costs included lost productivity, over the counter medicines, steroid induced morbidity and AMR costs.Add-on AZM resulted in a reduction in healthcare costs (mean (95% CI)) including nights in hospital (AUD 433.70 (AUD 48.59-818.81) or EUR 260.22 (EUR 29.15-491.29)), unplanned healthcare visits (AUD 20.25 (AUD 5.23-35.27) or EUR 12.15 (EUR 3.14-21.16)), antibiotic costs (AUD 14.88 (AUD 7.55-22.21) or EUR 8.93 (EUR 4.53-13.33)) and oral corticosteroid costs (AUD 4.73 (AUD 0.82-8.64) or EUR 2.84 (EUR 0.49-5.18)); all p<0.05. Overall healthcare and societal costs were lower (AUD 77.30 (EUR 46.38) and AUD 256.22 (EUR 153.73) respectively) albeit not statistically significant. The net monetary benefit of add-on AZM was estimated to be AUD 2072.30 (95% CI AUD 1348.55-2805.23) or (EUR 1243.38 (EUR 809.13-1683.14) assuming a willingness to pay per exacerbation avoided of AUD 2651 (EUR 1590.60). Irrespective of the sensitivity analysis applied, the net monetary benefit for total, moderate and severe exacerbations remained positive and significant.Add-on AZM therapy in poorly controlled asthma was a cost-effective therapy. Costs associated with AMR did not influence estimated cost-effectiveness.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. O'Neill C, Gibson PG, Heaney LG, et al. The cost-effectiveness of azithromycin in reducing exacerbations in uncontrolled asthma. Eur Respir J. 2021. PMID: 33008933. doi:10.1183/13993003.02436-2020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。